Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regen BioPharma (RGBP) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for Regen BioPharma (RGBP) over the last 4 years, with Q2 2025 value amounting to $23.8 million.

  • Regen BioPharma's Shares Outstanding (Diluted Average) rose 46370.9% to $23.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $23.8 million, marking a year-over-year increase of 46370.9%. This contributed to the annual value of $4.1 million for FY2024, which is 1620.89% up from last year.
  • Per Regen BioPharma's latest filing, its Shares Outstanding (Diluted Average) stood at $23.8 million for Q2 2025, which was up 46370.9% from $21.6 million recorded in Q1 2025.
  • Over the past 5 years, Regen BioPharma's Shares Outstanding (Diluted Average) peaked at $23.8 million during Q2 2025, and registered a low of $3.1 million during Q3 2022.
  • For the 4-year period, Regen BioPharma's Shares Outstanding (Diluted Average) averaged around $7.2 million, with its median value being $4.1 million (2024).
  • Per our database at Business Quant, Regen BioPharma's Shares Outstanding (Diluted Average) surged by 700.74% in 2023 and then surged by 46370.9% in 2025.
  • Regen BioPharma's Shares Outstanding (Diluted Average) (Quarter) stood at $3.4 million in 2022, then grew by 7.01% to $3.6 million in 2023, then grew by 14.3% to $4.1 million in 2024, then soared by 477.88% to $23.8 million in 2025.
  • Its last three reported values are $23.8 million in Q2 2025, $21.6 million for Q1 2025, and $4.1 million during Q4 2024.